After being informed about the study and risks, all patients giving written informed consent will undergo a screening period to determine eligibility for study entry.
At baseline patients who meet the eligibility requirements will be randomised in a double- blinded manner (patient and investigator) in a 1:1 ratio to nicotinamide riboside (1000 mg daily) or placebo (once a day)
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria.
Aged 18-65 years.
EDSS 3-6.5
Able to perform T25FW test
The participant must have documented evidence of disability progression observed during the 24 months before screening.
With or without a stable disease modifying therapy during the last three months.
Written informed consent for study participation.
You may not be if
A diagnosis of relapsing MS according to the revisions of the McDonald criteria
Neoplastic disease at baseline
Previous history of malignant melanoma or breast cancer
Stable phase of a progressive disease course
Pregnancy or lactating female patients
Dementia or other neurodegenerative disorder at baseline visit
Comorbidity (psychiatric or somatic) that precludes study participation
Use of high dose vitamin B3 supplementation within 30 days of enrolment
Genetically confirmed mitochondrial disease or metabolic disorder
Clareo Health | Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
